Skip to main content
. 2018 Jul 10;119(3):347–356. doi: 10.1038/s41416-018-0172-0

Table 1.

Sample sets utilised in the study

Number of samples Origin Subgroups Sequencing method
Sample set 1 55 Prostatectomy specimens of non-treated cancer, transurethral resection specimens of locally recurrent CRPC and BPH specimens obtained by several methods BPH (12), PC (30), locally recurrent CRPC (13) Whole genome and whole transcriptome/HiSeq
Sample set 2 80 Prostatectomy specimens of non-treated cancer, lymph node metastases collected during lymphadenectomy, metastatic CRPC specimens and noncancerous control specimens collected from 30 individuals at autopsy PC (24), lymph node metastasis (8), metastatic CRPC (30), noncancerous control (18) SureSelect targeted DNA and targeted RNA/MiSeq

BPH benign prostatic hyperplasia, PC prostate cancer, CRPC castration-resistant prostate cancer